In a pivotal study, SANCUSO provided sustained
5-day control of CINV34

  • SANCUSO provided complete control of CINV in 83.9% of patients at Day 5 in a pivotal clinical trial.35
    • Complete control was defined as no vomiting/retching, no more than mild nausea, and no rescue medication from the first dose to 24 hours after the last dose of chemotherapy34

 

Complete Control of CINV With SANCUSO by Chemotherapy Day35

Sancuso (Granisetron Transdermal System) provided complete control of chemotherapy induced nausea and vomiting (CINV) in 83.9% of patients in a pivotal clinical trial at day 5

A double-blind, phase III study of 582 patients randomized to receive either oral (2 mg/day for 3 to 5 days or transdermal granisetron (for 7 days) before receiving multi-day chemotherapy35

 

Consistent control achieved in cancer patients with difficult-to-treat chemotherapy regimens34

  • Patients received HEC or MEC multiday (3-5) regimens34
  • 71% of patients received platinum-based regimens (cisplatin)34
  • 72% of patients received chemotherapy for the first time34
  • The most common adverse event in patients receiving SANCUSO is constipation (5.4%)1

 

Learn how SANCUSO supports patient access